Bloom Burton & Co. Starts Eupraxia Pharmaceuticals (EPRX) at Buy (1) Feb 23, 2026 04:35PM
Raymond James Resumes Eupraxia Pharmaceuticals (EPRX) at Strong Buy Feb 19, 2026 04:48PM
Eupraxia Pharmaceuticals (EPRX) PT Raised to $19 at Cantor Fitzgerald Jan 15, 2026 07:20AM
Eupraxia reports positive tissue health data from EoE trial Jan 8, 2026 07:34AM
Eupraxia's (EPRX) Blockbuster Opportunity Not Fully Priced In - Cantor Fitzgerald Nov 14, 2025 07:03AM


Nov 13, 2025 05:00PM Eupraxia reports 52-week data showing sustained symptom relief from EP-104GI
Oct 2, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Eupraxia Pharmaceuticals (EPRX)
Sep 30, 2025 06:52AM Cantor Fitzgerald Reiterates Overweight Rating on Eupraxia Pharmaceuticals (EPRX)
Sep 29, 2025 05:00PM Eupraxia reports positive results from highest dose in EoE trial
Sep 26, 2025 06:47AM Cantor Fitzgerald Reiterates Overweight Rating on Eupraxia Pharmaceuticals (EPRX)
Sep 2, 2025 08:02AM Eupraxia reports sustained 12-month results from eosinophilic esophagitis trial
Aug 20, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Eupraxia Pharmaceuticals (EPRX)
Jun 26, 2025 06:07AM H.C. Wainwright Starts Eupraxia Pharmaceuticals (EPRX) at Buy
Jun 16, 2025 11:15AM Canaccord Genuity Starts Eupraxia Pharmaceuticals (EPRX:CN) (EPRX) at Spec. Buy
Feb 25, 2025 07:01AM Eupraxia Pharmaceuticals (EPRX) Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI
Feb 21, 2025 09:05AM Craig-Hallum Starts Eupraxia Pharmaceuticals (EPRX) at Buy
Feb 18, 2025 07:00AM Eupraxia Pharmaceuticals (EPRX) Announces CFO Succession
Nov 14, 2024 06:43AM Rodman & Renshaw Starts Eupraxia Pharmaceuticals (EPRX) at Buy
Oct 15, 2024 07:00AM Eupraxia Pharmaceuticals (EPRX) Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR
Oct 2, 2024 05:01PM Eupraxia Pharmaceuticals (EPRX) Strengthens Senior Management Team
Sep 11, 2024 07:01AM Eupraxia Pharmaceuticals (EPRX) Reports Data from RESOLVE Phase 1b/2a Trial of EP-104GI